AFMD News and Press, Affimed N.V. From 03/28/24

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full ye...

2024-03-14 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

2024-03-11 09:02:02 ET Affimed N.V. (AFMD) announced stock split at a ratio of 1-for-10 on 2024-03-11 ... Full story available on KlickAnalytics.com

2024-03-08 09:43:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Astra Space (NASDAQ: ASTR ) stock is in the news Friday after the U.S. space travel company revealed plans to go private . Astra Space is being taken private by a new parent...

2024-03-08 09:01:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AerSale (NASDAQ: ASLE ) stock is down on Friday after releasing its earnings report for the fourth quarter of 2023. The bad news for ASLE stockholders starts with the aftermarke...

2024-03-08 08:37:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company’s shares to undergo a reverse split later today ...

2024-03-06 06:47:44 ET More on Affimed Affimed CEO Adi Hoess to step down, Andreas Harstrick appointed interim CEO Affimed sells AbCheck unit for $6M Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial informa...

MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior appro...

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR- wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort Follow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still aw...